A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB)Capsule Summary

Clare L. Rogers, BSc Med (Hons); Matthew Gibson, MBBS, MMed (Clin Epi), DCH, FRACGP; Johannes S. Kern, MD, PhD, FEBDV, FACD; Linda K. Martin, MBBS(Hons), MMed(Clin Epi), FACD; Susan J. Robertson, MBBS, FACD; Benjamin S. Daniel, BCom, MBBS, MMed (Clin Epi), FACD; John C. Su, MBBS, MEpi, FRACP, FACD, FAAD; Oliver G.C. Murrell, BA; Grant Feng, BPsych, MDS; Dedee F. Murrell, MA, BMBCh, FAAD, MD, FACD

JAAD International (Mar 2021)

A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB)Capsule Summary

Clare L. Rogers, BSc Med (Hons),
Matthew Gibson, MBBS, MMed (Clin Epi), DCH, FRACGP,
Johannes S. Kern, MD, PhD, FEBDV, FACD,
Linda K. Martin, MBBS(Hons), MMed(Clin Epi), FACD,
Susan J. Robertson, MBBS, FACD,
Benjamin S. Daniel, BCom, MBBS, MMed (Clin Epi), FACD,
John C. Su, MBBS, MEpi, FRACP, FACD, FAAD,
Oliver G.C. Murrell, BA,
Grant Feng, BPsych, MDS,
Dedee F. Murrell, MA, BMBCh, FAAD, MD, FACD

Affiliations

Clare L. Rogers, BSc Med (Hons): Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia; Department of Dermatology, St George Hospital, Sydney, New South Wales, Australia; Premier Specialists, Dermatology Trials Australia, Kogarah, New South Wales, Australia
Matthew Gibson, MBBS, MMed (Clin Epi), DCH, FRACGP: Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia; Department of Dermatology, St George Hospital, Sydney, New South Wales, Australia; Premier Specialists, Dermatology Trials Australia, Kogarah, New South Wales, Australia
Johannes S. Kern, MD, PhD, FEBDV, FACD: Department of Dermatology, The Royal Melbourne Hospital, Parkville, Victoria, Australia; Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia
Linda K. Martin, MBBS(Hons), MMed(Clin Epi), FACD: Sydney Children's Hospital, Randwick, New South Wales, Australia
Susan J. Robertson, MBBS, FACD: Department of Dermatology, The Royal Melbourne Hospital, Parkville, Victoria, Australia; Department of Dermatology, The Royal Children's Hospital, Melbourne, Victoria, Australia; Murdoch Children's Research Institute, Melbourne, Victoria, Australia; Department of Dermatology, Monash Health, Melbourne, Victoria, Australia
Benjamin S. Daniel, BCom, MBBS, MMed (Clin Epi), FACD: Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia; Department of Dermatology, St George Hospital, Sydney, New South Wales, Australia
John C. Su, MBBS, MEpi, FRACP, FACD, FAAD: Department of Dermatology, The Royal Children's Hospital, Melbourne, Victoria, Australia; Murdoch Children's Research Institute, Melbourne, Victoria, Australia; Department of Dermatology, Monash Health, Melbourne, Victoria, Australia; Department of Pediatrics, The University of Melbourne, Melbourne, Victoria, Australia; Department of Medicine, Monash University, Melbourne, Victoria, Australia
Oliver G.C. Murrell, BA: Premier Specialists, Dermatology Trials Australia, Kogarah, New South Wales, Australia
Grant Feng, BPsych, MDS: Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
Dedee F. Murrell, MA, BMBCh, FAAD, MD, FACD: Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia; Department of Dermatology, St George Hospital, Sydney, New South Wales, Australia; Premier Specialists, Dermatology Trials Australia, Kogarah, New South Wales, Australia; Correspondence to: Dedee F. Murrell, MA, BMBCh, FAAD, MD, FACD, Department of Dermatology, St George Hospital, Sydney, New South Wales, 2217, Australia.

Journal volume & issue: Vol. 2
pp. 134 – 152

Abstract

Read online

Background: The success of clinical trials in Epidermolysis Bullosa (EB) is dependent upon the availability of a valid and reliable scoring tool that can accurately assess and monitor disease severity. The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB) were independently developed and validated against the Birmingham Epidermolysis Bullosa Severity Score but have never been directly compared. Objective: To compare the reliability, convergent validity, and discriminant validity of the EBDASI and iscorEB scoring tools. Methods: An observational cohort study was conducted in 15 patients with EB. Each patient was evaluated using the EBDASI and iscorEB-clinician scoring tools by 6 dermatologists with expertise in EB. Quality of life was assessed using the iscorEB-patient and Quality of Life in EB measures. Results: The intraclass correlation coefficients for interrater reliability were 0.942 for the EBDASI and 0.852 for the iscorEB-clinician. The intraclass correlation coefficients for intrarater reliability was 0.99 for both scores. The two tools demonstrated strong convergent validity with each other. Conclusion: Both scoring tools demonstrate excellent reliability. The EBDASI appears to better discriminate between EB types and disease severities.

Published in JAAD International

ISSN: 2666-3287 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Dermatology
Website: https://www.journals.elsevier.com/jaad-international

About the journal

Abstract

Keywords